Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Effects of Inhalable Microparticles of Socheongryong-tang on Chronic Obstructive Pulmonary Disease in a Mouse Model

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2013, v.34 no.3, pp.54-68






  • Downloaded
  • Viewed

Abstract

Objectives: This study aimed to evaluate the effects of microparticles of Socheongryong-tang (SCRT) on chronic obstructive pulmonary disease (COPD) in a mouse model. Methods: The inhalable microparticles containing SCRT were produced by spray-drying with leucine as an excipient, and evaluated with respect to the aerodynamic properties of the powder by Andersen cascade impactor (ACI). Its equivalence to SCRT extract was evaluated using lipopolysaccharide (LPS) and a cigarette-smoking (CS)-induced murine COPD model. Results: SCRT microparticles provided desirable aerodynamic properties (fine particle fraction of 49.6±5.5% and mass median aerodynamic diameter of 4.8±0.3 ㎛). SCRT microparticles did not show mortality or clinical signs over 14 days. Also there were no significant differences in body weight, organ weights or serum chemical parameters between SCRT microparticle-treated and non-treated groups. After 14 days the platelet count significantly increased compared with the non-treated group, but the values were within the normal range. Inhalation of SCRT microparticles decreased the rate of neutrophils in blood, granulocytes in peripheral blood mononuclear cells (PBMC) and bronchoalveolar lavage fluid (BALF) and level of TNF-α and IL-6 in BALF on COPD mouse model induced by LPS plus CS. This effect was verified by histological findings including immunofluorescence staining of elastin, collagen, and caspase 3 protein in lung tissue. Conclusions: These data demonstrate that SCRT microparticles are equivalent to SCRT extract in pharmaceutical properties for COPD. This study suggests that SCRT microparticles would be a potential agent of inhalation therapy for the treatment of COPD.

keywords
Socheongryong-tang, inhalable microparticles, chronic obstructive pulmonary disease, spray drying, cigarette smoking


Reference

1

1. Statistics Korea. Cause of death statistics 2011. 2012;[2screens]. Available at: URL:http://kosis.kr/ups/ups_01List01.jsp?pubcode=YD. Accessed Sep 20, 2012.

2

2. Mannino DM, Kiriz VA. Changing the burden ofCOPD mortality. Int J Chron Obstruct Pulmon Dis. 2006;1(3):219-33.

3

3. Mannino DM. COPD: epidemiology, prevalence, morbidityand mortality, and disease heterogeneity. Chest2002;121:121S 26S.

4

4. Celli BR, MacNee W. Standards for the diagnosis andtreatment of patients with COPD: a summary of theATS/ERS position paper. Eur Respir J. 2004;23(6):932-46.

5

5. Barnes PJ, Hansel TT. Prospects for new drugs forchronic obstructive pulmonary disease. Lancet. 2004;364(9438):985-96.

6

6. Jung SK, Jung HJ, Kim JD, Choi HY, Park MY, ParkYC, et al. Pye-gye-nae-gwa-hak. Seoul: Nado.2011:510-1.

7

7. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S,et al. Herbal Formula, PM014, Attenuates LungInflammation in a Murine Model of ChronicObstructive Pulmonary Disease. Evid BasedComplement Alternat Med. 2012;2012:769830. Epub2012 Jun 12.

8

8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC.Protective effects of Socheongryong-tang onElastase-Induced Lung Injury. J Korean Oriental Med.2011;32(4):83-99.

9

9. Yoon JM, Park YC. Protective effects ofSeonpyejeongcheon-tang on Elastase-induced LungInjury. J Korean Oriental Med. 2010;31(1):84-101.

10

10. Choi HJ, Bang NY, Song BW, Kim NJ, RhyuBH. Survey on the preference for the dosageforms of oriental herbal medicine. KyungheeMedicine. 2004;20(1):46-57.

11

11. Derendorf H, Nave R, Drollmann A, Cerasoli F,Wurst W. Relevance of pharmacokinetics andpharmacodynamics of inhaled corticosteroids toasthma. Eur Respir J. 2006;28(5):1042-50.

12

12. Courrier HM, Butz N, Vandamme TF.Pulmonary drug delivery systems: recent developmentsand prospects. Crit Rev Ther DrugCarrier Syst. 2002;19(4-5):425-98.

13

13. Zhang J. Shang-han-za-bing-lun. Shijiazhuang.Hebei Kezue Jishu Chubanshe. 1994. p.27.

14

14. Jung S, Cho SJ, Moon KI, Kim HW, Kim BY,Cho SI. Effects of Socheongryong-Tang onImmunoglobulin Production in Asthmatic Mice.Kor. J. Herbology. 2008;23(1):23-8.

15

15. Kim KY, Lee JH, Kim YJ, Choi SY, Kim TH,Lyu YS, et al. Anti-allergic effects ofSocheongyoung-tang on RBL-2H3 mast cell andmice-mediated allergy model. Korean J. OrientalPhysiology & Pathology. 2007;21(5):1260-70.

16

16. Hwang WS, Lee JS, Choi JY, Jung HJ, Rhee HK,Jung SK. Two Cases of Chronic Sinusitis withAsthma Improved by Socheongryong-tang. JKorean Oriental Med. 2003;24(1):207-12.

17

17. Jung SK, Heo TS, Hwang WS, Ju CY, Kim YW,Jung HJ. The Effects of Sochongryong-tang onSerum IL-4, IL-5, and IFN-γ in asthmaticPatients. J Korean Oriental Med. 2002;23(2):70-7.

18

18. Ibrahim BM, Jun SW, Lee MY, Kang SH, YeoY. Development of inhalable dry powder formulationof basic fibroblast growth factor. Int JPharm. 2010;385(1-2):66-72.

19

19. Thiel CG. Cascade impactor data and the lognormaldistribution: nonlinear regression for abetter fit. J Aerosol Med. 2002;15(4):369-78.

20

20. Nemzek JA, Bolgos GL, Williams BA, RemickDG. Differences in normal values for murinewhite blood cell counts and other hematologicalparameters based on sampling site. Inflamm Res.2001;50(10):523-7.

21

21. Hillery AM, Lloyd AW, Swarbrick J. Drug deliveryand targeting; for pharmacists and pharmaceuticalscientists. London:Taylor and Francis.2001:2.

22

22. Tayab ZR, Hochhaus G. Pharmacokinetic/pharmacodynamicevaluation of inhalation drugs: applicationto targeted pulmonary delivery systems.Expert Opin Drug Deliv. 2005;2(3):519-32.

23

23. Rabe KF, Hurd S, Anzueto A, Barnes PJ, BuistSA, Calverley P, et al. Global strategy for thediagnosis, management, and prevention of chronicobstructive pulmonary disease: GOLD executivesummary. Am J Respir Crit Care Med.2007;176(6):532-55.

24

24. Geller DE. Comparing clinical features of thenebulizer, metered-dose inhaler, and dry powderinhaler. Respir Care. 2005;50(10):1313-21.

25

25. Borgstrom L. On the use of dry powder inhalersin situations perceived as constrained. J AerosolMed. 2001;14(3):281-7.

26

26. Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y.Mannitol-guided delivery of Ciprofloxacin in artificialcystic fibrosis mucus model. BiotechnolBioeng. 2011;108(6):1441-9.

27

27. Yang Y, Tsifansky MD, Wu CJ, Yang HI,Schmidt G, Yeo Y. Inhalable antibiotic deliveryusing a dry powder co-delivering recombinantdeoxyribonuclease and ciprofloxacin for treatmentof cystic fibrosis. Pharm Res. 2010;27(1):151-60.

28

28. Lipworth BJ. Targets for inhaled treatment.Respir Med. 2000;94:S13-6.

29

29. Azarmi S, Lobenberg R, Roa WH, Tai S, FinlayWH. Formulation and in vivo evaluation of effervescentinhalable carrier particles for pulmonarydelivery of nanoparticles. Drug Dev Ind Pharm.2008;34(9):943-7.

30

30. Molfino NA, Jeffery PK. Chronic obstructivepulmonary disease: Histopathology, inflammationand potential therapies. PulmPharmacol Ther. 2007;20(5):462-72.

31

31. Yoo CG. Pathogenesis and pathophysiology ofCOPD. The Korean Journal of Medicine.2009;77:383-400.

32

32. Niewoehner DE, Kleinerman J, Rice DB.Pathologic changes in the peripheral airways ofyoung cigarette smokers. N Engl J Med.1974;291(15):755-8.

33

33. Schaberg T, Haller H, Rau M, Kaiser D,Fassbender M, Lode H. Superoxide anion releaseinduced by platelet-activating factor is increasedin human alveolar macrophages from smokers.Eur Respir J. 1992;5(4):387-93.

34

34. Wright JL, Cosio M, Churg A. Animal modelsof chronic obstructive pulmonary disease. Am JPhysiol Lung Cell Mol Physiol. 2008;295(1):L1-15

35

35. Wright JL, Sun JP. Effect of smoking cessationon pulmonary and cardiovascular function andstructure: analysis of guinea pig model. J ApplPhysiol. 1994;76(5):2163-8.

36

36. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaledcorticosteroids for stable chronic obstructive pulmonarydisease. Cochrane Database Syst Rev.2012;7:CD002991.

37

37. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y,Yamaguchi E, Miyamoto K, et al. Increased levelsof interleukin-8 in BAL fluid from smokerssusceptible to pulmonary emphysema. Thorax.2002;57(5):405-11.

38

38. Keatings VM, Collins PD, Scott DM, Barnes PJ.Differences in interleukin-8 and tumor necrosisfactor-alpha in induced sputum from patientswith chronic obstructive pulmonary disease orasthma. Am J Respir Crit Care Med. 1996;153(2):530-4.

39

39. Demedts IK, Demoor T, Bracke KR, Joos GF,Brusselle GG. Role of apoptosis in the pathogenesisof COPD and pulmonary emphysema.Respir Res. 2006;7:53.

40

40. Foronjy R, D'Armiento J. The role of collagenasein emphysema. Respir Res. 2001;2(6):348-52.

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Journal of Korean Medicine